Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

109.30
+0.95000.88%
Post-market: 109.300.00000.00%19:30 EDT
Volume:1.04M
Turnover:112.60M
Market Cap:9.09B
PE:-34.03
High:110.04
Open:106.52
Low:104.19
Close:108.35
52wk High:130.05
52wk Low:55.26
Shares:83.15M
Float Shares:66.33M
Volume Ratio:1.09
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.02
PE(LYR):-29.62

Loading ...

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral Stat6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

THOMSON REUTERS
·
Sep 01

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

GlobeNewswire
·
Sep 01

Kymera Therapeutics Price Target Raised to $151.00/Share from $116.00 by Wells Fargo

Dow Jones
·
Aug 27

Kymera Therapeutics Speeds Pipeline Amid Rising Spend

TIPRANKS
·
Aug 21

Kymera Therapeutics on Track for Record High Closing

Dow Jones
·
Aug 17

Kymera Therapeutics (KYMR) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Aug 13

Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)

TIPRANKS
·
Aug 11

Immunic Appoints Elena Ridloff to Board of Directors

Reuters
·
Aug 11

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

MT Newswires Live
·
Aug 11

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Reuters
·
Aug 07

Analyst Reiterates Buy on Kymera, Citing Favorable BROADEN2 Design and Compelling KT-621 Risk-Reward in Atopic Dermatitis

TIPRANKS
·
Aug 06

Kymera Therapeutics, Inc. : Citigroup Raises Target Price to $135 from $120

THOMSON REUTERS
·
Aug 06

Kymera Therapeutics price target raised to $139 from $133 at Barclays

TIPRANKS
·
Aug 06

Tenaya Therapeutics Q2 Net Loss Widens on Impairment Charge

Reuters
·
Aug 06

Vir Biotechnology Q2 Revenue Up, Beats Estimates on Astellas Payment

Reuters
·
Aug 06

Biopharma Firm Xencor's Q2 Revenue Beats on Royalty Revenue, Milestone Payments

Reuters
·
Aug 06

Editas Medicine Q2 Net Loss Narrows and Beats Estimates

Reuters
·
Aug 06

Kymera Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Kymera Therapeutics Posts Corporate Deck Outlining Push to Develop Oral Targeted Protein Degraders for Immunology

Reuters
·
Aug 05

Kymera Q2 2026 Earnings: Milestone Revenue Narrows Net Loss

TradingKey
·
Aug 05